Literature DB >> 26759403

To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity.

Tejaswi Bommireddy1, Zia Iqbal Carrim1.   

Abstract

We report a case of a patient with treated breast cancer whose dilated fundus examination showed crystalline deposits in the central region of the macula. She was taking tamoxifen for secondary prevention. Optical coherence tomography revealed individual refractile deposits associated with intraretinal cysts in both eyes. Tamoxifen-related retinopathy was suspected. A decision to discontinue treatment with tamoxifen was considered but had to be taken in conjunction with the oncologist. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26759403      PMCID： PMC4716368          DOI： 10.1136/bcr-2015-213431

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  10 in total

Review 1.  The differential diagnosis of crystals in the retina.

Authors:  F Nadim; H Walid; J Adib
Journal:  Int Ophthalmol       Date:  2001       Impact factor: 2.031

2.  Ocular toxicity in low-dose tamoxifen: a prospective study.

Authors:  B N Noureddin; M Seoud; Z Bashshur; Z Salem; A Shamseddin; A Khalil
Journal:  Eye (Lond)       Date:  1999-12       Impact factor: 3.775

3.  Ocular toxicity during adjuvant chemoendocrine therapy for early breast cancer: results from International Breast Cancer Study Group trials.

Authors:  Lorenzo Gianni; Ilaria Panzini; Sigui Li; Richard D Gelber; John Collins; Stig B Holmberg; Diana Crivellari; Monica Castiglione-Gertsch; Aron Goldhirsch; Alan S Coates; Alberto Ravaioli
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

Review 4.  Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients.

Authors:  N A Pavlidis; C Petris; E Briassoulis; G Klouvas; C Psilas; J Rempapis; G Petroutsos
Journal:  Cancer       Date:  1992-06-15       Impact factor: 6.860

Review 5.  Retinal changes associated with tamoxifen treatment for breast cancer.

Authors:  R Tang; J Shields; J Schiffman; H Li; D Locher; J Hampton; T Prager; G Pardo
Journal:  Eye (Lond)       Date:  1997       Impact factor: 3.775

6.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

7.  Tamoxifen retinopathy.

Authors:  M I Kaiser-Kupfer; M E Lippman
Journal:  Cancer Treat Rep       Date:  1978-03

Review 8.  Tamoxifen-associated eye disease. A review.

Authors:  S G Nayfield; M B Gorin
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

9.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Authors:  B Fisher; J P Costantino; D L Wickerham; C K Redmond; M Kavanah; W M Cronin; V Vogel; A Robidoux; N Dimitrov; J Atkins; M Daly; S Wieand; E Tan-Chiu; L Ford; N Wolmark
Journal:  J Natl Cancer Inst       Date:  1998-09-16       Impact factor: 13.506

10.  Screening for ocular toxicity in asymptomatic patients treated with tamoxifen.

Authors:  J S Heier; R A Dragoo; R W Enzenauer; W J Waterhouse
Journal:  Am J Ophthalmol       Date:  1994-06-15       Impact factor: 5.258
  10 in total
  1 in total

1.  The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient.

Authors:  Chuanyu Li; Jun Xiao; He Zou; Bo Yang; Lifu Luo
Journal:  BMC Ophthalmol       Date:  2021-05-07       Impact factor: 2.209
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.